← Back to Clinical Trials
Recruiting Phase 2, Phase 3 NCT06423729
Effect of Nicorandil in Type 2 Diabetic Obese Patients
Trial Parameters
Condition Diabetes Mellitus, Type 2
Sponsor Tanta University
Study Type INTERVENTIONAL
Phase Phase 2, Phase 3
Enrollment 46
Sex ALL
Min Age 18 Years
Max Age 60 Years
Start Date 2024-06-01
Completion 2024-12
Interventions
Nicorandil 10 MG
Brief Summary
1. Evaluating the effect of nicorandil on glycemic control of diabetic obese patients treated with sulfonylureas. 2. Investigating the effect of nicorandil on body weight of diabetic obese patients treated with sulfonylureas.
Eligibility Criteria
Inclusion Criteria: * Diabetes duration ranged from 1 to 10 years. * Body mass index (BMI) \>30 Kg/m2. * The selected patients are treated with sulfonylureas alone. * The age of selected patient ranged from 18 and 60 years. Exclusion Criteria: * Pregnant and lactating females. * Patients with hypersensitivity to nicorandil. * Uncontrolled hypertension and its antihypertensive medications * Severe renal or hepatic disease.
Related Trials
NCT06638567
Postoperative Basal Bolus or Sliding Scale Insulin Regimen in DM2 and Its Effect on Surgical Site In
View Trial →
NCT07299084
A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food
View Trial →
NCT06423729
Effect of Nicorandil in Type 2 Diabetic Obese Patients
View Trial →